Pembrolizumab

Evidence Level: L5

Predicted Indications: 9

Pembrolizumab

Pharmacist Assessment Report

Pembrolizumab: From Non-Small Cell Lung Cancer and Metastatic Melanoma to Fibromatosis, Gingival

One-Sentence Summary

Pembrolizumab is a PD-1 immune checkpoint inhibitor, originally used to treat non-small cell lung cancer, lung cancer and metastatic melanoma. The TxGNN model predicts it may be effective for gingival fibromatosis, but no clinical trials and no publications were found for this indication, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Non-small cell lung cancer, lung cancer, metastatic melanoma (the Canadian licence record contains no indication text)
Predicted New Indication	Fibromatosis, gingival
TxGNN Prediction Score	0.9940
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Pembrolizumab is known to be a monoclonal antibody that targets programmed cell death protein 1 (PD-1, PDCD1). Blocking PD-1 releases the brake on T cells so that they can attack tumour cells. Its efficacy in melanoma and lung cancer is well established.

Gingival fibromatosis, however, is a benign, usually hereditary, overgrowth of gum tissue. It is not a cancer and has no known dependence on PD-1/PD-L1 biology. Immune activation is not an expected treatment strategy for it. The high score therefore looks like a statistical artefact of the model rather than a biologically grounded link, and no mechanistic rationale could be identified.

The other top-ranked predictions show the same pattern. Most are benign or rare genetic conditions (for example inclusion body myopathy, ovarioleukodystrophy, lung hamartoma and lung fibroma) with no plausible PD-1 rationale. A few are lung cancer subtypes (lung hilum carcinoma, pulmonary sulcus neoplasm) that are largely covered by the existing NSCLC indication, so they are not distinct repurposing opportunities.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02456869	KEYTRUDA	Not specified	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 monoclonal antibody), not a conventional cytotoxic agent
Myelosuppression Risk	Low. Direct myelosuppression is not a characteristic effect, but immune-related haematological adverse events can occur
Emetogenicity Classification	Low
Monitoring Items	Please refer to the package insert warnings and precautions. Immune-related adverse events are generally monitored through blood counts, liver, renal and thyroid function
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions (13 records found; none is specific to the predicted indication):

Major: lenalidomide, pomalidomide, thalidomide
Moderate: corticosteroids, including hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone, methylprednisolone and deflazacort
Target pharmacology: the antibody acts on PD-1 (PDCD1)

Package insert warnings and contraindications for Canada were not available in the data compiled for this report. Please refer to the package insert for these.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no supporting clinical trials, literature or mechanistic rationale (Evidence Level L5). Gingival fibromatosis is a benign condition for which immune checkpoint blockade is not expected to help. It also carries a risk of serious immune-related adverse events, so the risk-benefit balance is unfavourable on current information.

To proceed, the following is needed:

A biological rationale linking PD-1 signalling to gingival fibromatosis (for example preclinical or tissue-level data)
Mechanism of action data
Health Canada package insert warnings and contraindications
Indication text for the Canadian licence (DIN 02456869)
If any repurposing direction is pursued, consider the lung cancer subtypes (lung hilum carcinoma, pulmonary sulcus neoplasm) only after checking whether the existing NSCLC approval already covers them
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.